The Canadian Association of Pathologists and its National Standards Committee for High Complexity Testing (CAP-ACP NSCHCT) identified the need to generate and publish Canadian guidelines to assist clinical laboratories in setting up predictive PD-L1 IHC testing. These guidelines do not pertain to the professional practice of oncologists; they pertain solely to the development and validation of PD-L1 testing by clinical laboratories. 

Prior to submission for peer-reviewed publication, we invite CAP-ACP members to review and provide comments on the draft recommendations during this open review period of April 15-30, 2019.

Fit-For-Purpose PD-L1 Biomarker Testing in Immuno-Oncology: Guidelines for Clinical Laboratories
From the Canadian Association of Pathologists – Assciation canadienne des pathologistes (CAP-ACP)

References

Comments should be emailed directly to our supporting agency for this review period, to the attention of Sonia Hoole at soniahoole@precisionrxdx.com. We ask that reviewer’s contact details are included with their comments so that we may ask for further clarification directly as necessary. 

I thank you for your time and consideration.

Sincerely
Dr Emina Torlakovic
Chair, CAP-ACP NSCHCLT / IHC
https://www.cap-acp.org/NatStdsCttee.php


- last updated September 2019 -